Biodexa Pharmaceuticals Plc (BDRX) Price Target Analysis

Analyst Rating:

Based on 0 analysts

No Target Data

BDRX trades at Wall Street's consensus target of —.

Current Price$3.01

Average Target—

Low—

Median—

High—

Analyst Target Range

Forward P/E—

PEG Ratio—

Implied Growth—

Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$3.01

Consensus—

High—

Low—

Consensus Scenario Assumptions

The base valuation assumes BDRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings

No analyst coverage available for BDRX

Coverage appears once Wall Street estimates are published.

BDRX Price Target Analysis

Updated June 23, 2026

As of June 23, 2026, Biodexa Pharmaceuticals Plc (BDRX) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $679709.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.

From a valuation perspective, BDRX trades at a trailing P/E of -0.0x.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis

Avg Peer Upside

+96.7%

Industry Consensus

Avg Forward P/E

36.3x

(Growth Premium)

Peers with Coverage

9 / 10

Active Analyst Tracking

Company	Market Cap	Price	Target	Upside Potential	Rating	Fwd P/E	Analysts
SIGASIGA Technologies, Inc.	$311M	$4.33	—	—	Buy	2.5x	1
NUVBNuvation Bio Inc.	$2.0B	$5.76	$13.00	+133.8%	Buy	—	9
IMVTImmunovant, Inc.	$7.8B	$38.10	$45.00	+27.3%	Buy	—	23
PRAXPraxis Precision Medicines, Inc.	$8.8B	$303.00	$584.00	+106.9%	Buy	—	16
ACADACADIA Pharmaceuticals Inc.	$3.8B	$22.09	$33.67	+55.7%	Buy	55.6x	37
INVAInnoviva, Inc.	$1.7B	$22.67	$37.00	+64.5%	Buy	6.3x	10
AVXLAnavex Life Sciences Corp.	$235M	$2.54	$11.00	+302.9%	Buy	—	13
CORTCorcept Therapeutics Incorporated	$8.6B	$79.71	$83.00	+3.9%	Buy	136.5x	26
AGENAgenus Inc.	$127M	$3.04	$7.33	+144.3%	Buy	3.8x	11
IQVIQVIA Holdings Inc.	$28.5B	$167.83	$219.44	+30.8%	Buy	13.1x	44

BDRX — Frequently Asked Questions

Quick answers to the most common questions about buying BDRX stock.

What is the BDRX stock price target for 2026?

The consensus price target for BDRX is $N/A, close to the current price of $3.01 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.

Is BDRX a buy, sell, or hold?

BDRX has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is BDRX stock overvalued or undervalued?

BDRX's current price is $3.01 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.

How high can BDRX stock go?

The most bullish Wall Street analyst has a price target of $N/A for BDRX, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.

How many analysts cover BDRX stock?

BDRX is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the BDRX stock forecast?

The 12-month BDRX stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".

Should I buy BDRX stock?

BDRX appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do BDRX price targets vary so much?

BDRX analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.

Consensus-Based Analysis Tools